PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
15319543-10	2004	Indeed, epinephrine translocated PKC or cPLA2 from cytosol to membrane fraction.	Epinephrine	8-19	cytosolic phospholipase A2	Oryctolagus cuniculus	40-45
28420991-3	2017	Gabapentin treatment significantly (p < 0.05) attenuated cytokines production, cPLA2 activation, COX-2 expression, and PGE2 levels in SIRC.	Gabapentin	0-10	cytosolic phospholipase A2	Oryctolagus cuniculus	82-87
23644101-0	2013	Effects of sevoflurane on pulmonary cytosolic phospholipase A2 and clara cell secretory protein expressions in rabbits with one-lung ventilation-induced lung injury.	Sevoflurane	11-22	cytosolic phospholipase A2	Oryctolagus cuniculus	36-62
23644101-6	2013	Compared with OLV group, the OLV+sevoflurane groups showed significantly increased expressions of CCSP and reduced C-PLA2 expression, lung W/D ratios and histological scores (P<0.05).	Sevoflurane	33-44	cytosolic phospholipase A2	Oryctolagus cuniculus	115-121
23644101-9	2013	Sevoflurane can protect against OLV-induced acute lung injury possibly by inhibiting C-PLA2 expression via up-regulation of CCSP expressions or through other mechanisms resulting in down-regulated expression of C-PLA2.	Sevoflurane	0-11	cytosolic phospholipase A2	Oryctolagus cuniculus	85-91
23644101-9	2013	Sevoflurane can protect against OLV-induced acute lung injury possibly by inhibiting C-PLA2 expression via up-regulation of CCSP expressions or through other mechanisms resulting in down-regulated expression of C-PLA2.	Sevoflurane	0-11	cytosolic phospholipase A2	Oryctolagus cuniculus	211-217
18187403-3	2008	We have studied the sites of cPLA(2) phosphorylation and their significance in arachidonic acid (AA) release in response to norepinephrine (NE) in vivo in rabbit vascular smooth muscle cells (VSMCs) using specific anti-phospho-S515- and -S505 cPLA(2) antibodies and by mutagenesis of S515 and S505 to alanine.	Arachidonic Acid	79-95	cytosolic phospholipase A2	Oryctolagus cuniculus	29-35
18187403-3	2008	We have studied the sites of cPLA(2) phosphorylation and their significance in arachidonic acid (AA) release in response to norepinephrine (NE) in vivo in rabbit vascular smooth muscle cells (VSMCs) using specific anti-phospho-S515- and -S505 cPLA(2) antibodies and by mutagenesis of S515 and S505 to alanine.	Norepinephrine	124-138	cytosolic phospholipase A2	Oryctolagus cuniculus	29-35
14644748-11	2004	In conclusion, ANG II inhibited alpha-MG uptake via PKC-MAPK-cPLA2 signal cascade through the AT1 receptor in the PTCs.	alpha-mg	32-40	cytosolic phospholipase A2	Oryctolagus cuniculus	61-66
30015951-0	2018	Sevoflurane attenuates ventilator-induced lung injury by regulating c-PLA2 expression.	Sevoflurane	0-11	cytosolic phospholipase A2	Oryctolagus cuniculus	68-74
30015951-7	2018	Sevoflurane inhalation in the OLV-treated group induced an upregulation of CCSP and a downregulation of c-PLA2 expression.	Sevoflurane	0-11	cytosolic phospholipase A2	Oryctolagus cuniculus	104-110
30015951-8	2018	In the group NAO, in which the club cells were simultaneously exfoliated, OLV caused more severe lung damage and induced higher expression of c-PLA2 compared with that in group O.	10-N-nonylacridinium orange	13-16	cytosolic phospholipase A2	Oryctolagus cuniculus	142-148
30015951-9	2018	However, sevoflurane inhalation reduced the extent of lung injury and the expression of c-PLA2, even when the endogenous modulator of lung inflammation, CCSP, was exfoliated (group NAOF).	Sevoflurane	9-20	cytosolic phospholipase A2	Oryctolagus cuniculus	88-94
19885021-6	2009	ATP depletion caused arachidonic acid release and increased mRNA levels of cytosolic phospholipase A(2) (cPLA(2)).	Adenosine Triphosphate	0-3	cytosolic phospholipase A2	Oryctolagus cuniculus	75-112
19885021-7	2009	The ATP depletion-dependent arachidonic acid release was inhibited by cPLA(2) specific inhibitor AACOCF(3).	Adenosine Triphosphate	4-7	cytosolic phospholipase A2	Oryctolagus cuniculus	70-77
19885021-7	2009	The ATP depletion-dependent arachidonic acid release was inhibited by cPLA(2) specific inhibitor AACOCF(3).	Arachidonic Acid	28-44	cytosolic phospholipase A2	Oryctolagus cuniculus	70-77
19885021-10	2009	These results indicate that ATP depletion-induced alterations in membrane transport function and cell viability are due to reactive oxygen species generation and cPLA(2) activation in renal proximal tubular cells.	Adenosine Triphosphate	28-31	cytosolic phospholipase A2	Oryctolagus cuniculus	162-169
15705737-1	2005	Cytosolic phospholipase A(2) (cPLA(2)) is activated and translocated to the nuclear envelope by various vasoactive agents, including norepinephrine (NE), and releases arachidonic acid (AA) from tissue phospholipids.	Norepinephrine	133-147	cytosolic phospholipase A2	Oryctolagus cuniculus	0-37
15705737-1	2005	Cytosolic phospholipase A(2) (cPLA(2)) is activated and translocated to the nuclear envelope by various vasoactive agents, including norepinephrine (NE), and releases arachidonic acid (AA) from tissue phospholipids.	Arachidonic Acid	167-183	cytosolic phospholipase A2	Oryctolagus cuniculus	0-37
15705737-1	2005	Cytosolic phospholipase A(2) (cPLA(2)) is activated and translocated to the nuclear envelope by various vasoactive agents, including norepinephrine (NE), and releases arachidonic acid (AA) from tissue phospholipids.	Phospholipids	201-214	cytosolic phospholipase A2	Oryctolagus cuniculus	0-37
15705737-6	2005	Cytochalasin D (CD; 0.5 microM) and latrunculin A (LA; 0.5 microM) that disrupted actin filaments, blocked cPLA(2) translocation elicited by NE.	Cytochalasin D	0-14	cytosolic phospholipase A2	Oryctolagus cuniculus	107-114
15705737-6	2005	Cytochalasin D (CD; 0.5 microM) and latrunculin A (LA; 0.5 microM) that disrupted actin filaments, blocked cPLA(2) translocation elicited by NE.	latrunculin A	36-49	cytosolic phospholipase A2	Oryctolagus cuniculus	107-114
15229103-0	2004	Oxalate inhibits renal proximal tubule cell proliferation via oxidative stress, p38 MAPK/JNK, and cPLA2 signaling pathways.	Oxalates	0-7	cytosolic phospholipase A2	Oryctolagus cuniculus	98-103
15229103-8	2004	Oxalate stimulated [(3)H]AA release and translocation of cytosolic phospholipase A(2) (cPLA(2)) from the cytosolic fraction to the membrane fraction.	Oxalates	0-7	cytosolic phospholipase A2	Oryctolagus cuniculus	87-93
15229103-11	2004	These findings suggest that oxalate inhibits renal PTC proliferation via oxidative stress, p38 MAPK/JNK, and cPLA(2) signaling pathways.	Oxalates	28-35	cytosolic phospholipase A2	Oryctolagus cuniculus	109-115
15319543-11	2004	In conclusion, epinephrine partially inhibits the alpha-MG uptake through PKA, PKC, p44/42, p38 MAPK, and cPLA2 pathways in the PTCs.	Epinephrine	15-26	cytosolic phospholipase A2	Oryctolagus cuniculus	106-111
15319543-11	2004	In conclusion, epinephrine partially inhibits the alpha-MG uptake through PKA, PKC, p44/42, p38 MAPK, and cPLA2 pathways in the PTCs.	methylglucoside	50-58	cytosolic phospholipase A2	Oryctolagus cuniculus	106-111
12538832-0	2003	Norepinephrine-induced stimulation of p38 mitogen-activated protein kinase is mediated by arachidonic acid metabolites generated by activation of cytosolic phospholipase A(2) in vascular smooth muscle cells.	Norepinephrine	0-14	cytosolic phospholipase A2	Oryctolagus cuniculus	146-173
12591927-4	2003	ATP significantly increased arachidonic acid production, which involved the activation of the 85-kDa cytosolic phospholipase A(2) (cPLA(2)) but not a secreted form of PLA(2), as demonstrated by various PLA(2) inhibitors and translocation experiments.	Adenosine Triphosphate	0-3	cytosolic phospholipase A2	Oryctolagus cuniculus	101-138
12591927-4	2003	ATP significantly increased arachidonic acid production, which involved the activation of the 85-kDa cytosolic phospholipase A(2) (cPLA(2)) but not a secreted form of PLA(2), as demonstrated by various PLA(2) inhibitors and translocation experiments.	Arachidonic Acid	28-44	cytosolic phospholipase A2	Oryctolagus cuniculus	101-138
12538832-0	2003	Norepinephrine-induced stimulation of p38 mitogen-activated protein kinase is mediated by arachidonic acid metabolites generated by activation of cytosolic phospholipase A(2) in vascular smooth muscle cells.	Arachidonic Acid	90-106	cytosolic phospholipase A2	Oryctolagus cuniculus	146-173
12538832-3	2003	The purpose of this study was to determine the contribution of cPLA(2)-generated arachidonic acid (AA) and its metabolites to the activation of p38 MAPK measured by its phosphorylation, in response to NE in rabbit VSMC.	Arachidonic Acid	81-97	cytosolic phospholipase A2	Oryctolagus cuniculus	63-70
12482921-0	2003	CaM kinase IIalpha mediates norepinephrine-induced translocation of cytosolic phospholipase A2 to the nuclear envelope.	Norepinephrine	28-42	cytosolic phospholipase A2	Oryctolagus cuniculus	68-94
12482921-1	2003	Several growth factors, hormones and neurotransmitters, including norepinephrine, increase cellular calcium levels, promoting the translocation of cytosolic phospholipase A(2) to the nuclear envelope.	Norepinephrine	66-80	cytosolic phospholipase A2	Oryctolagus cuniculus	147-174
12482921-1	2003	Several growth factors, hormones and neurotransmitters, including norepinephrine, increase cellular calcium levels, promoting the translocation of cytosolic phospholipase A(2) to the nuclear envelope.	Calcium	100-107	cytosolic phospholipase A2	Oryctolagus cuniculus	147-174
12482921-2	2003	This study was conducted to investigate the contributions of the calcium-binding protein calmodulin and of calcium-calmodulin-dependent protein kinase II to cytosolic phospholipase A(2) translocation to the nuclear envelope elicited by norepinephrine in rabbit aortic smooth-muscle cells.	Norepinephrine	236-250	cytosolic phospholipase A2	Oryctolagus cuniculus	157-184
12482921-3	2003	Norepinephrine caused cytosolic phospholipase A(2) accumulation around the nuclear envelope as determined from its immunofluorescence; cytosolic phospholipase A(2) translocation was blocked by inhibitors of calmodulin and calcium-calmodulin-dependent protein kinase II or calcium-calmodulin-dependent protein kinase IIalpha antisense oligonucleotide.	Norepinephrine	0-14	cytosolic phospholipase A2	Oryctolagus cuniculus	22-49
12482921-3	2003	Norepinephrine caused cytosolic phospholipase A(2) accumulation around the nuclear envelope as determined from its immunofluorescence; cytosolic phospholipase A(2) translocation was blocked by inhibitors of calmodulin and calcium-calmodulin-dependent protein kinase II or calcium-calmodulin-dependent protein kinase IIalpha antisense oligonucleotide.	Oligonucleotides	334-349	cytosolic phospholipase A2	Oryctolagus cuniculus	135-162
12482921-4	2003	Calmodulin and calcium-calmodulin-dependent protein kinase II inhibitors did not prevent cytosolic calcium increase but attenuated cytosolic phospholipase A(2) phosphorylation caused by norepinephrine or ionomycin.	Calcium	15-22	cytosolic phospholipase A2	Oryctolagus cuniculus	131-158
12482921-4	2003	Calmodulin and calcium-calmodulin-dependent protein kinase II inhibitors did not prevent cytosolic calcium increase but attenuated cytosolic phospholipase A(2) phosphorylation caused by norepinephrine or ionomycin.	Norepinephrine	186-200	cytosolic phospholipase A2	Oryctolagus cuniculus	131-158
12482921-4	2003	Calmodulin and calcium-calmodulin-dependent protein kinase II inhibitors did not prevent cytosolic calcium increase but attenuated cytosolic phospholipase A(2) phosphorylation caused by norepinephrine or ionomycin.	Ionomycin	204-213	cytosolic phospholipase A2	Oryctolagus cuniculus	131-158
12482921-6	2003	Recombinant cytosolic phospholipase A(2) phosphorylated by purified calcium-calmodulin-dependent protein kinase II, but not unphosphorylated or dephosphorylated cytosolic phospholipase A(2), introduced into permeabilized vascular smooth-muscle cells in the absence of calcium accumulated around the nuclear envelope.	Calcium	68-75	cytosolic phospholipase A2	Oryctolagus cuniculus	12-39
12482921-7	2003	These data suggest that norepinephrine-induced translocation of cytosolic phospholipase A(2) to the nuclear envelope is mediated by its phosphorylation by calcium-calmodulin-dependent protein kinase II and that calcium alone is insufficient for cytosolic phospholipase A(2) translocation to the nuclear envelope in rabbit vascular smooth-muscle cells.	Norepinephrine	24-38	cytosolic phospholipase A2	Oryctolagus cuniculus	64-91
12482921-7	2003	These data suggest that norepinephrine-induced translocation of cytosolic phospholipase A(2) to the nuclear envelope is mediated by its phosphorylation by calcium-calmodulin-dependent protein kinase II and that calcium alone is insufficient for cytosolic phospholipase A(2) translocation to the nuclear envelope in rabbit vascular smooth-muscle cells.	Norepinephrine	24-38	cytosolic phospholipase A2	Oryctolagus cuniculus	245-272
12482921-7	2003	These data suggest that norepinephrine-induced translocation of cytosolic phospholipase A(2) to the nuclear envelope is mediated by its phosphorylation by calcium-calmodulin-dependent protein kinase II and that calcium alone is insufficient for cytosolic phospholipase A(2) translocation to the nuclear envelope in rabbit vascular smooth-muscle cells.	Calcium	155-162	cytosolic phospholipase A2	Oryctolagus cuniculus	64-91
12410540-8	2002	Tanshinone I was found to be an inhibitor of type IIA human recombinant sPLA(2)(IC(50) = 11 microM) and rabbit recombinant cPLA(2) (IC(50) = 82 microM).	tanshinone	0-12	cytosolic phospholipase A2	Oryctolagus cuniculus	123-130
11408559-0	2001	Cytosolic phospholipase A2 activation by the p38 kinase inhibitor SB203580 in rabbit aortic smooth muscle cells.	SB 203580	66-74	cytosolic phospholipase A2	Oryctolagus cuniculus	0-26
11849446-0	2002	High glucose down-regulates angiotensin II binding via the PKC-MAPK-cPLA2 signal cascade in renal proximal tubule cells.	Glucose	5-12	cytosolic phospholipase A2	Oryctolagus cuniculus	68-73
11849446-15	2002	CONCLUSION: High glucose down-regulates (125)I-Ang II binding via the PKC-MAPK-cPLA2 signal pathway.	Glucose	17-24	cytosolic phospholipase A2	Oryctolagus cuniculus	79-84
11408559-2	2001	Here we report that SB203580, which blocked p38 kinase activation elicited by anisomycin, increased the phosphorylation and activity of cytosolic phospholipase A2 (cPLA2) and arachidonic acid (AA) release in quiescent vascular smooth muscle cells from rabbit aortae.	SB 203580	20-28	cytosolic phospholipase A2	Oryctolagus cuniculus	136-162
11408559-2	2001	Here we report that SB203580, which blocked p38 kinase activation elicited by anisomycin, increased the phosphorylation and activity of cytosolic phospholipase A2 (cPLA2) and arachidonic acid (AA) release in quiescent vascular smooth muscle cells from rabbit aortae.	SB 203580	20-28	cytosolic phospholipase A2	Oryctolagus cuniculus	164-169
11408559-2	2001	Here we report that SB203580, which blocked p38 kinase activation elicited by anisomycin, increased the phosphorylation and activity of cytosolic phospholipase A2 (cPLA2) and arachidonic acid (AA) release in quiescent vascular smooth muscle cells from rabbit aortae.	Anisomycin	78-88	cytosolic phospholipase A2	Oryctolagus cuniculus	136-162
11408559-4	2001	The increase in CaMKII activity and cPLA2 phosphorylation caused by SB203580 was attenuated by CaMKII inhibitor KN-93, indicating involvement of CaMKII in cPLA2 phosphorylation by this compound.	SB 203580	68-76	cytosolic phospholipase A2	Oryctolagus cuniculus	36-41
11408559-4	2001	The increase in CaMKII activity and cPLA2 phosphorylation caused by SB203580 was attenuated by CaMKII inhibitor KN-93, indicating involvement of CaMKII in cPLA2 phosphorylation by this compound.	SB 203580	68-76	cytosolic phospholipase A2	Oryctolagus cuniculus	155-160
11408559-4	2001	The increase in CaMKII activity and cPLA2 phosphorylation caused by SB203580 was attenuated by CaMKII inhibitor KN-93, indicating involvement of CaMKII in cPLA2 phosphorylation by this compound.	KN 93	112-117	cytosolic phospholipase A2	Oryctolagus cuniculus	36-41
11408559-4	2001	The increase in CaMKII activity and cPLA2 phosphorylation caused by SB203580 was attenuated by CaMKII inhibitor KN-93, indicating involvement of CaMKII in cPLA2 phosphorylation by this compound.	KN 93	112-117	cytosolic phospholipase A2	Oryctolagus cuniculus	155-160
11408559-6	2001	SB203580-induced cPLA2 phosphorylation was inhibited by depletion of Ca2+ from the medium, by the voltage-operated Ca2+ channel blocker nifedipine, and by the calmodulin inhibitor W-7.	SB 203580	0-8	cytosolic phospholipase A2	Oryctolagus cuniculus	17-22
11408559-6	2001	SB203580-induced cPLA2 phosphorylation was inhibited by depletion of Ca2+ from the medium, by the voltage-operated Ca2+ channel blocker nifedipine, and by the calmodulin inhibitor W-7.	Nifedipine	136-146	cytosolic phospholipase A2	Oryctolagus cuniculus	17-22
11408559-7	2001	cPLA2 translocation from cytoplasm to the nuclear envelope caused by SB203580 was also inhibited in the absence of extracellular Ca2+.	SB 203580	69-77	cytosolic phospholipase A2	Oryctolagus cuniculus	0-5
11408559-9	2001	These data suggest that SB203580 not only inhibits p38 kinase activity but also increases Ca2+ influx through voltage-sensitive Ca2+ channels, which promotes cPLA2 translocation to the nuclear envelope, and by interacting with calmodulin, activates CaMKII and cPLA2 and releases AA.	SB 203580	24-32	cytosolic phospholipase A2	Oryctolagus cuniculus	158-163
11408559-9	2001	These data suggest that SB203580 not only inhibits p38 kinase activity but also increases Ca2+ influx through voltage-sensitive Ca2+ channels, which promotes cPLA2 translocation to the nuclear envelope, and by interacting with calmodulin, activates CaMKII and cPLA2 and releases AA.	SB 203580	24-32	cytosolic phospholipase A2	Oryctolagus cuniculus	260-265
11278912-15	2001	We conclude that NE stimulates cPLA(2)-dependent PLD(2) through lipoxygenase- and CYP4A-derived HETEs via the Ras/ERK pathway by a mechanism involving tyrosine phosphorylation of PLD(2) in rabbit VSMC.	Tyrosine	151-159	cytosolic phospholipase A2	Oryctolagus cuniculus	31-38
11089546-4	2000	The concentrations of cytosolic phospholipase A2, which generates arachidonic acid for PGE2 synthesis, and PGH endoperoxide synthases (types 1 and 2), which catalyze the conversion of arachidonic acid to prostanoids, rose substantially in rabbit amnion at term.	Arachidonic Acid	66-82	cytosolic phospholipase A2	Oryctolagus cuniculus	22-48
11230346-2	2001	Ang II also activates ras/mitogen-activated protein (MAP) kinase in VSMCs; this activation is mediated by 20-hydroxyeicosatetraenoic acid (HETE) and 12(S)-HETE, which are metabolites of arachidonic acid generated by cytochrome P450 4A and lipoxygenase, respectively, produced on activation of cPLA(2).	20-hydroxy-5,8,11,14-eicosatetraenoic acid	106-137	cytosolic phospholipase A2	Oryctolagus cuniculus	293-300
11230346-2	2001	Ang II also activates ras/mitogen-activated protein (MAP) kinase in VSMCs; this activation is mediated by 20-hydroxyeicosatetraenoic acid (HETE) and 12(S)-HETE, which are metabolites of arachidonic acid generated by cytochrome P450 4A and lipoxygenase, respectively, produced on activation of cPLA(2).	20-hydroxy-5,8,11,14-eicosatetraenoic acid	139-143	cytosolic phospholipase A2	Oryctolagus cuniculus	293-300
11230346-3	2001	The purpose of this study was to determine if Ang II-induced PLD activation in VSMCs is mediated through the ras/extracellular signal-regulating kinase (ERK) pathway by arachidonic acid metabolites that are generated consequent to cPLA(2) stimulation.	Arachidonic Acid	169-185	cytosolic phospholipase A2	Oryctolagus cuniculus	231-238
11230346-6	2001	Ang II-induced PLD activation was decreased by the inhibitor methyl arachidonylfluorophosphate (MAFP) and the antisense oligonucleotide of cPLA(2).	Oligonucleotides	120-135	cytosolic phospholipase A2	Oryctolagus cuniculus	139-146
11230346-11	2001	These data suggest that the CYP4A metabolite 20-HETE, which is generated from arachidonic acid after cPLA(2) activation by Ang II, stimulates the ras/MAP kinase pathway, which in turn activates PLD2 and releases further arachidonic acid for prostaglandin synthesis through the phosphatidate phosphohydrolase/diacylglycerol lipase pathway.	20-Hete	45-52	cytosolic phospholipase A2	Oryctolagus cuniculus	101-108
11230346-11	2001	These data suggest that the CYP4A metabolite 20-HETE, which is generated from arachidonic acid after cPLA(2) activation by Ang II, stimulates the ras/MAP kinase pathway, which in turn activates PLD2 and releases further arachidonic acid for prostaglandin synthesis through the phosphatidate phosphohydrolase/diacylglycerol lipase pathway.	Arachidonic Acid	78-94	cytosolic phospholipase A2	Oryctolagus cuniculus	101-108
11230346-11	2001	These data suggest that the CYP4A metabolite 20-HETE, which is generated from arachidonic acid after cPLA(2) activation by Ang II, stimulates the ras/MAP kinase pathway, which in turn activates PLD2 and releases further arachidonic acid for prostaglandin synthesis through the phosphatidate phosphohydrolase/diacylglycerol lipase pathway.	Arachidonic Acid	220-236	cytosolic phospholipase A2	Oryctolagus cuniculus	101-108
11230346-11	2001	These data suggest that the CYP4A metabolite 20-HETE, which is generated from arachidonic acid after cPLA(2) activation by Ang II, stimulates the ras/MAP kinase pathway, which in turn activates PLD2 and releases further arachidonic acid for prostaglandin synthesis through the phosphatidate phosphohydrolase/diacylglycerol lipase pathway.	Prostaglandins	241-254	cytosolic phospholipase A2	Oryctolagus cuniculus	101-108
11278912-0	2001	Phospholipase D activation by norepinephrine is mediated by 12(s)-, 15(s)-, and 20-hydroxyeicosatetraenoic acids generated by stimulation of cytosolic phospholipase a2.	Norepinephrine	30-44	cytosolic phospholipase A2	Oryctolagus cuniculus	141-167
11278912-0	2001	Phospholipase D activation by norepinephrine is mediated by 12(s)-, 15(s)-, and 20-hydroxyeicosatetraenoic acids generated by stimulation of cytosolic phospholipase a2.	12(s)-, 15(s)-, and 20-hydroxyeicosatetraenoic acids	60-112	cytosolic phospholipase A2	Oryctolagus cuniculus	141-167
11278912-4	2001	Arachidonic acid (AA) released by cPLA(2)-catalyzed phospholipid hydrolysis is then metabolized into hydroxyeicosatetraenoic acids (HETEs) through lipoxygenase and cytochrome P450 4A (CYP4A) pathways.	Arachidonic Acid	0-16	cytosolic phospholipase A2	Oryctolagus cuniculus	34-41
11278912-4	2001	Arachidonic acid (AA) released by cPLA(2)-catalyzed phospholipid hydrolysis is then metabolized into hydroxyeicosatetraenoic acids (HETEs) through lipoxygenase and cytochrome P450 4A (CYP4A) pathways.	Phospholipids	52-64	cytosolic phospholipase A2	Oryctolagus cuniculus	34-41
11278912-4	2001	Arachidonic acid (AA) released by cPLA(2)-catalyzed phospholipid hydrolysis is then metabolized into hydroxyeicosatetraenoic acids (HETEs) through lipoxygenase and cytochrome P450 4A (CYP4A) pathways.	Hydroxyeicosatetraenoic Acids	101-130	cytosolic phospholipase A2	Oryctolagus cuniculus	34-41
11278912-4	2001	Arachidonic acid (AA) released by cPLA(2)-catalyzed phospholipid hydrolysis is then metabolized into hydroxyeicosatetraenoic acids (HETEs) through lipoxygenase and cytochrome P450 4A (CYP4A) pathways.	Hydroxyeicosatetraenoic Acids	132-137	cytosolic phospholipase A2	Oryctolagus cuniculus	34-41
11278912-8	2001	Blockade of cPLA(2) activity or protein depletion with selective cPLA(2) antisense oligonucleotides abolished NE-induced PLD activation.	Oligonucleotides	83-99	cytosolic phospholipase A2	Oryctolagus cuniculus	65-72
11089546-4	2000	The concentrations of cytosolic phospholipase A2, which generates arachidonic acid for PGE2 synthesis, and PGH endoperoxide synthases (types 1 and 2), which catalyze the conversion of arachidonic acid to prostanoids, rose substantially in rabbit amnion at term.	Dinoprostone	87-91	cytosolic phospholipase A2	Oryctolagus cuniculus	22-48
11089546-4	2000	The concentrations of cytosolic phospholipase A2, which generates arachidonic acid for PGE2 synthesis, and PGH endoperoxide synthases (types 1 and 2), which catalyze the conversion of arachidonic acid to prostanoids, rose substantially in rabbit amnion at term.	Arachidonic Acid	184-200	cytosolic phospholipase A2	Oryctolagus cuniculus	22-48
11089546-4	2000	The concentrations of cytosolic phospholipase A2, which generates arachidonic acid for PGE2 synthesis, and PGH endoperoxide synthases (types 1 and 2), which catalyze the conversion of arachidonic acid to prostanoids, rose substantially in rabbit amnion at term.	Prostaglandins	204-215	cytosolic phospholipase A2	Oryctolagus cuniculus	22-48
11089546-8	2000	These findings show that the rapid stimulation of PGE2 synthesis by OT occurs through cytosolic phospholipase A2 activation and PGH endoperoxide synthase-1 activity, both of which, along with OT receptor concentrations, are considerably up-regulated in the amnion at the end of gestation.	Dinoprostone	50-54	cytosolic phospholipase A2	Oryctolagus cuniculus	86-112
10892858-7	2000	EGF-induced PGE2 production was suppressed by AACOCF3, a phospholipase A2 (cPLA2) inhibitor.	Dinoprostone	12-16	cytosolic phospholipase A2	Oryctolagus cuniculus	75-80
9770549-1	1998	Norepinephrine (NE) and angiotensin II (Ang II), by promoting extracellular Ca2+ influx, increase Ca2+/calmodulin-dependent kinase II (CaMKII) activity, leading to activation of mitogen-activated protein kinase (MAPK) and cytosolic phospholipase A2 (cPLA2), resulting in release of arachidonic acid (AA) for prostacyclin synthesis in rabbit vascular smooth muscle cells.	Norepinephrine	0-14	cytosolic phospholipase A2	Oryctolagus cuniculus	222-248
10795906-2	2000	The two major enzyme systems involved are cytosolic phospholipase A2 (cPLA2), which catalyses the formation of arachidonic acid from membrane glycerophospholipids, and prostaglandin endoperoxide-H synthases-1 and -2, which allow conversion of arachidonic acid to prostaglandins.	Arachidonic Acid	111-127	cytosolic phospholipase A2	Oryctolagus cuniculus	42-68
10795906-2	2000	The two major enzyme systems involved are cytosolic phospholipase A2 (cPLA2), which catalyses the formation of arachidonic acid from membrane glycerophospholipids, and prostaglandin endoperoxide-H synthases-1 and -2, which allow conversion of arachidonic acid to prostaglandins.	Arachidonic Acid	111-127	cytosolic phospholipase A2	Oryctolagus cuniculus	70-75
10795906-2	2000	The two major enzyme systems involved are cytosolic phospholipase A2 (cPLA2), which catalyses the formation of arachidonic acid from membrane glycerophospholipids, and prostaglandin endoperoxide-H synthases-1 and -2, which allow conversion of arachidonic acid to prostaglandins.	Glycerophospholipids	142-162	cytosolic phospholipase A2	Oryctolagus cuniculus	42-68
10795906-2	2000	The two major enzyme systems involved are cytosolic phospholipase A2 (cPLA2), which catalyses the formation of arachidonic acid from membrane glycerophospholipids, and prostaglandin endoperoxide-H synthases-1 and -2, which allow conversion of arachidonic acid to prostaglandins.	Glycerophospholipids	142-162	cytosolic phospholipase A2	Oryctolagus cuniculus	70-75
10795906-2	2000	The two major enzyme systems involved are cytosolic phospholipase A2 (cPLA2), which catalyses the formation of arachidonic acid from membrane glycerophospholipids, and prostaglandin endoperoxide-H synthases-1 and -2, which allow conversion of arachidonic acid to prostaglandins.	Prostaglandins	168-181	cytosolic phospholipase A2	Oryctolagus cuniculus	70-75
10795906-2	2000	The two major enzyme systems involved are cytosolic phospholipase A2 (cPLA2), which catalyses the formation of arachidonic acid from membrane glycerophospholipids, and prostaglandin endoperoxide-H synthases-1 and -2, which allow conversion of arachidonic acid to prostaglandins.	Arachidonic Acid	243-259	cytosolic phospholipase A2	Oryctolagus cuniculus	42-68
10795906-2	2000	The two major enzyme systems involved are cytosolic phospholipase A2 (cPLA2), which catalyses the formation of arachidonic acid from membrane glycerophospholipids, and prostaglandin endoperoxide-H synthases-1 and -2, which allow conversion of arachidonic acid to prostaglandins.	Arachidonic Acid	243-259	cytosolic phospholipase A2	Oryctolagus cuniculus	70-75
10795906-2	2000	The two major enzyme systems involved are cytosolic phospholipase A2 (cPLA2), which catalyses the formation of arachidonic acid from membrane glycerophospholipids, and prostaglandin endoperoxide-H synthases-1 and -2, which allow conversion of arachidonic acid to prostaglandins.	Prostaglandins	263-277	cytosolic phospholipase A2	Oryctolagus cuniculus	42-68
10795906-2	2000	The two major enzyme systems involved are cytosolic phospholipase A2 (cPLA2), which catalyses the formation of arachidonic acid from membrane glycerophospholipids, and prostaglandin endoperoxide-H synthases-1 and -2, which allow conversion of arachidonic acid to prostaglandins.	Prostaglandins	263-277	cytosolic phospholipase A2	Oryctolagus cuniculus	70-75
10521370-7	1999	Dexamethasone (2 micromol/L), which also inhibited the HDL-induced PGI(2) release, reduced significantly both Cox-2 mRNA and protein levels without affecting cPLA(2) and Cox-1 protein levels.	Dexamethasone	0-13	cytosolic phospholipase A2	Oryctolagus cuniculus	158-165
9880803-8	1999	These results suggest that ceramide triggers PLC activation through its synergistic action with thrombin, and subsequently potentiates the sequential PKC-MAPK cascade-cPLA2 pathway, thus resulting in enhancement of arachidonic acid release.	Ceramides	27-35	cytosolic phospholipase A2	Oryctolagus cuniculus	167-172
9880803-1	1999	To study the involvement of sphingolipids in glycerophospholipid metabolism, the contribution of ceramide to the activation of group IV cytosolic phospholipase A2 (cPLA2) was investigated in platelets using cell-permeable C6-ceramide (N-hexanoylsphingosine).	Ceramides	97-105	cytosolic phospholipase A2	Oryctolagus cuniculus	164-169
9880803-1	1999	To study the involvement of sphingolipids in glycerophospholipid metabolism, the contribution of ceramide to the activation of group IV cytosolic phospholipase A2 (cPLA2) was investigated in platelets using cell-permeable C6-ceramide (N-hexanoylsphingosine).	N-caproylsphingosine	222-233	cytosolic phospholipase A2	Oryctolagus cuniculus	164-169
9880803-1	1999	To study the involvement of sphingolipids in glycerophospholipid metabolism, the contribution of ceramide to the activation of group IV cytosolic phospholipase A2 (cPLA2) was investigated in platelets using cell-permeable C6-ceramide (N-hexanoylsphingosine).	N-caproylsphingosine	235-256	cytosolic phospholipase A2	Oryctolagus cuniculus	164-169
9880803-2	1999	The addition of ceramide led to potentiation of thrombin-induced activation of cPLA2 and mitogen-activated protein kinase (MAPK) as well as arachidonic acid release and lysophosphatidylcholine formation.	Ceramides	16-24	cytosolic phospholipase A2	Oryctolagus cuniculus	79-84
9770549-1	1998	Norepinephrine (NE) and angiotensin II (Ang II), by promoting extracellular Ca2+ influx, increase Ca2+/calmodulin-dependent kinase II (CaMKII) activity, leading to activation of mitogen-activated protein kinase (MAPK) and cytosolic phospholipase A2 (cPLA2), resulting in release of arachidonic acid (AA) for prostacyclin synthesis in rabbit vascular smooth muscle cells.	Norepinephrine	0-14	cytosolic phospholipase A2	Oryctolagus cuniculus	250-255
9770549-6	1998	An AA metabolite of CYP450, 20-hydroxyeicosatetraenoic acid (20-HETE), increased the activities of MAPK and cPLA2 and caused translocation of Ras.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	28-59	cytosolic phospholipase A2	Oryctolagus cuniculus	108-113
9770549-6	1998	An AA metabolite of CYP450, 20-hydroxyeicosatetraenoic acid (20-HETE), increased the activities of MAPK and cPLA2 and caused translocation of Ras.	20-hydroxy-5,8,11,14-eicosatetraenoic acid	61-68	cytosolic phospholipase A2	Oryctolagus cuniculus	108-113
9770549-7	1998	These data suggest that activation of MAPK by NE, Ang II, and EGF is mediated by a signaling mechanism involving 20-HETE, which is generated by stimulation of cPLA2 by CaMKII.	Hydroxyeicosatetraenoic Acids	116-120	cytosolic phospholipase A2	Oryctolagus cuniculus	159-164
9435202-8	1998	The CaM kinase II inhibitor KN-93 and the MAP kinase kinase inhibitor PD-98059 attenuated both Ang-(1-7)- and Ang II-induced cPLA2 activity and [3H]AA release.	KN 93	28-33	cytosolic phospholipase A2	Oryctolagus cuniculus	125-130
9495265-5	1998	However, membrane-associated PLA2 did not demonstrate significant substrate specificity, whereas 1-steroyl-2-[14C]arachidonylphosphatidyl choline was the preferred substrate for cPLA2.	1-steroyl-2-[14c]arachidonylphosphatidyl choline	97-145	cytosolic phospholipase A2	Oryctolagus cuniculus	178-183
9435679-2	1997	BK-stimulated AA release was reduced 92% by arachidonyl trifluoromethyl ketone, an inhibitor of cytosolic PLA2 (cPLA2).	arachidonyltrifluoromethane	44-78	cytosolic phospholipase A2	Oryctolagus cuniculus	96-110
9435679-2	1997	BK-stimulated AA release was reduced 92% by arachidonyl trifluoromethyl ketone, an inhibitor of cytosolic PLA2 (cPLA2).	arachidonyltrifluoromethane	44-78	cytosolic phospholipase A2	Oryctolagus cuniculus	112-117
9435679-3	1997	Examination of PLA2 activity in vitro demonstrated that BK stimulation resulted in a greater than twofold increase in PLA2 activity and that this activity was dithiothreitol insensitive and was inhibited by an antibody directed against cPLA2.	Dithiothreitol	159-173	cytosolic phospholipase A2	Oryctolagus cuniculus	236-241
9435679-6	1997	cPLA2 activity stimulated by phorbol ester [phorbol 12-myristate 13-acetate (PMA)] displayed a similar degree of activation and was associated with an increase in serine phosphorylation identical to that caused by BK.	Phorbol Esters	29-42	cytosolic phospholipase A2	Oryctolagus cuniculus	0-5
9435679-6	1997	cPLA2 activity stimulated by phorbol ester [phorbol 12-myristate 13-acetate (PMA)] displayed a similar degree of activation and was associated with an increase in serine phosphorylation identical to that caused by BK.	Tetradecanoylphorbol Acetate	44-75	cytosolic phospholipase A2	Oryctolagus cuniculus	0-5
9435679-6	1997	cPLA2 activity stimulated by phorbol ester [phorbol 12-myristate 13-acetate (PMA)] displayed a similar degree of activation and was associated with an increase in serine phosphorylation identical to that caused by BK.	Tetradecanoylphorbol Acetate	77-80	cytosolic phospholipase A2	Oryctolagus cuniculus	0-5
9435679-6	1997	cPLA2 activity stimulated by phorbol ester [phorbol 12-myristate 13-acetate (PMA)] displayed a similar degree of activation and was associated with an increase in serine phosphorylation identical to that caused by BK.	Serine	163-169	cytosolic phospholipase A2	Oryctolagus cuniculus	0-5
9435202-8	1998	The CaM kinase II inhibitor KN-93 and the MAP kinase kinase inhibitor PD-98059 attenuated both Ang-(1-7)- and Ang II-induced cPLA2 activity and [3H]AA release.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	70-78	cytosolic phospholipase A2	Oryctolagus cuniculus	125-130
9385440-0	1997	Stimulation of cytosolic phospholipase A2-catalyzed arachidonic acid liberation by low dose tert-butyl hydroperoxide without an influence on the enzyme activity in rabbit platelets.	Arachidonic Acid	52-68	cytosolic phospholipase A2	Oryctolagus cuniculus	15-41
9385440-0	1997	Stimulation of cytosolic phospholipase A2-catalyzed arachidonic acid liberation by low dose tert-butyl hydroperoxide without an influence on the enzyme activity in rabbit platelets.	tert-Butylhydroperoxide	92-116	cytosolic phospholipase A2	Oryctolagus cuniculus	15-41
9385440-1	1997	The effect of lipid peroxide on the hydrolytic action of cytosolic phospholipase A2 (cPLA2) in rabbit platelets was investigated.	Lipid Peroxides	14-28	cytosolic phospholipase A2	Oryctolagus cuniculus	57-83
9385440-1	1997	The effect of lipid peroxide on the hydrolytic action of cytosolic phospholipase A2 (cPLA2) in rabbit platelets was investigated.	Lipid Peroxides	14-28	cytosolic phospholipase A2	Oryctolagus cuniculus	85-90
9385440-5	1997	However, with a membrane fraction, arachidonic acid liberation catalyzed by the partially purified cPLA2 was synergistically enhanced by BHP and FeSO4.	Arachidonic Acid	35-51	cytosolic phospholipase A2	Oryctolagus cuniculus	99-104
9385440-5	1997	However, with a membrane fraction, arachidonic acid liberation catalyzed by the partially purified cPLA2 was synergistically enhanced by BHP and FeSO4.	tert-Butylhydroperoxide	137-140	cytosolic phospholipase A2	Oryctolagus cuniculus	99-104
9385440-5	1997	However, with a membrane fraction, arachidonic acid liberation catalyzed by the partially purified cPLA2 was synergistically enhanced by BHP and FeSO4.	ferrous sulfate	145-150	cytosolic phospholipase A2	Oryctolagus cuniculus	99-104
9385440-6	1997	These results suggest that oxidative stress may potentiate the hydrolytic action of cPLA2 on membrane phospholipids without an influence on the processes leading to the enzyme activation.	Phospholipids	102-115	cytosolic phospholipase A2	Oryctolagus cuniculus	84-89
8939965-0	1996	Calcium/calmodulin-dependent protein kinase IIalpha mediates activation of mitogen-activated protein kinase and cytosolic phospholipase A2 in norepinephrine-induced arachidonic acid release in rabbit aortic smooth muscle cells.	Norepinephrine	142-156	cytosolic phospholipase A2	Oryctolagus cuniculus	112-138
9211348-6	1997	Compared to adults, neonates had a lower renal cortical cytosolic PLA2 (cPLA2) activity, assessed as the release of 14C-arachidonic acid (AA) from labeled phosphatidyl choline (0.44 +/- 0.10 vs. 0.74 +/- 0.06% 14C-AA released/min/mg protein, P < 0.05) and microsomal PLA2 activity (0.32 +/- 0.03 vs. 1.20 +/- 0.13% 14C-AA released/min/mg protein, P < 0.001).	14c-arachidonic acid	116-136	cytosolic phospholipase A2	Oryctolagus cuniculus	72-77
9211348-6	1997	Compared to adults, neonates had a lower renal cortical cytosolic PLA2 (cPLA2) activity, assessed as the release of 14C-arachidonic acid (AA) from labeled phosphatidyl choline (0.44 +/- 0.10 vs. 0.74 +/- 0.06% 14C-AA released/min/mg protein, P < 0.05) and microsomal PLA2 activity (0.32 +/- 0.03 vs. 1.20 +/- 0.13% 14C-AA released/min/mg protein, P < 0.001).	Phosphatidylcholines	155-175	cytosolic phospholipase A2	Oryctolagus cuniculus	72-77
9211348-6	1997	Compared to adults, neonates had a lower renal cortical cytosolic PLA2 (cPLA2) activity, assessed as the release of 14C-arachidonic acid (AA) from labeled phosphatidyl choline (0.44 +/- 0.10 vs. 0.74 +/- 0.06% 14C-AA released/min/mg protein, P < 0.05) and microsomal PLA2 activity (0.32 +/- 0.03 vs. 1.20 +/- 0.13% 14C-AA released/min/mg protein, P < 0.001).	Carbon-14	116-119	cytosolic phospholipase A2	Oryctolagus cuniculus	56-70
9211348-6	1997	Compared to adults, neonates had a lower renal cortical cytosolic PLA2 (cPLA2) activity, assessed as the release of 14C-arachidonic acid (AA) from labeled phosphatidyl choline (0.44 +/- 0.10 vs. 0.74 +/- 0.06% 14C-AA released/min/mg protein, P < 0.05) and microsomal PLA2 activity (0.32 +/- 0.03 vs. 1.20 +/- 0.13% 14C-AA released/min/mg protein, P < 0.001).	Carbon-14	116-119	cytosolic phospholipase A2	Oryctolagus cuniculus	72-77
9211348-6	1997	Compared to adults, neonates had a lower renal cortical cytosolic PLA2 (cPLA2) activity, assessed as the release of 14C-arachidonic acid (AA) from labeled phosphatidyl choline (0.44 +/- 0.10 vs. 0.74 +/- 0.06% 14C-AA released/min/mg protein, P < 0.05) and microsomal PLA2 activity (0.32 +/- 0.03 vs. 1.20 +/- 0.13% 14C-AA released/min/mg protein, P < 0.001).	Carbon-14	210-213	cytosolic phospholipase A2	Oryctolagus cuniculus	72-77
9503430-5	1997	ZT-A caused phosphorylation and activation of mitogenactivated protein kinase (MAPK), which was known to activate cytosolic phospholipase A2 (cPLA2).	zooxanthellatoxin A	0-4	cytosolic phospholipase A2	Oryctolagus cuniculus	114-140
9503430-5	1997	ZT-A caused phosphorylation and activation of mitogenactivated protein kinase (MAPK), which was known to activate cytosolic phospholipase A2 (cPLA2).	zooxanthellatoxin A	0-4	cytosolic phospholipase A2	Oryctolagus cuniculus	142-147
8939965-0	1996	Calcium/calmodulin-dependent protein kinase IIalpha mediates activation of mitogen-activated protein kinase and cytosolic phospholipase A2 in norepinephrine-induced arachidonic acid release in rabbit aortic smooth muscle cells.	Arachidonic Acid	165-181	cytosolic phospholipase A2	Oryctolagus cuniculus	112-138
8939965-5	1996	Treatment of cells with PD-098059, a MAP kinase kinase inhibitor, or with MAP kinase antisense oligonucleotide reduced NE-induced activation of MAP kinase and cPLA2.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	24-33	cytosolic phospholipase A2	Oryctolagus cuniculus	159-164
8939965-5	1996	Treatment of cells with PD-098059, a MAP kinase kinase inhibitor, or with MAP kinase antisense oligonucleotide reduced NE-induced activation of MAP kinase and cPLA2.	Oligonucleotides	95-110	cytosolic phospholipase A2	Oryctolagus cuniculus	159-164
8939965-6	1996	NE-induced MAP kinase and cPLA2 activation was also inhibited in cells treated with a CaM kinase II inhibitor, KN-93, or with CaM kinase II antisense oligonucleotide.	KN 93	111-116	cytosolic phospholipase A2	Oryctolagus cuniculus	26-31
8939965-6	1996	NE-induced MAP kinase and cPLA2 activation was also inhibited in cells treated with a CaM kinase II inhibitor, KN-93, or with CaM kinase II antisense oligonucleotide.	Oligonucleotides	150-165	cytosolic phospholipase A2	Oryctolagus cuniculus	26-31
8939965-9	1996	Collectively, these data suggest that CaM kinase II can activate MAP kinase, which in turn activates cPLA2 to release AA for prostacyclin synthesis in the rabbit VSMC.	Epoprostenol	125-137	cytosolic phospholipase A2	Oryctolagus cuniculus	101-106
8939965-11	1996	Activation of adrenergic receptors with NE in VSMC caused translocation of CaM kinase II, MAP kinase, and cPLA2 to the nuclear envelope only in the presence of extracellular Ca2+.	vsmc	46-50	cytosolic phospholipase A2	Oryctolagus cuniculus	106-111
8939965-13	1996	Therefore, it appears that in rabbit VSMC, NE, by promoting extracellular Ca2+ influx, increases CaM kinase II activity, leading to activation of MAP kinase and cPLA2 and translocation to the nuclear envelope, resulting in release of AA from the nuclear envelope for prostacyclin synthesis.	vsmc	37-41	cytosolic phospholipase A2	Oryctolagus cuniculus	161-166
8719419-0	1995	Effect of berbamine on cytosolic phospholipase A2 activation in rabbit platelets.	berbamine	10-19	cytosolic phospholipase A2	Oryctolagus cuniculus	23-49
8913345-0	1996	Involvement of mitogen-activated protein kinase and translocation of cytosolic phospholipase A2 to the nuclear envelope in acetylcholine-induced prostacyclin synthesis in rabbit coronary endothelial cells.	Acetylcholine	123-136	cytosolic phospholipase A2	Oryctolagus cuniculus	69-95
8913345-0	1996	Involvement of mitogen-activated protein kinase and translocation of cytosolic phospholipase A2 to the nuclear envelope in acetylcholine-induced prostacyclin synthesis in rabbit coronary endothelial cells.	Epoprostenol	145-157	cytosolic phospholipase A2	Oryctolagus cuniculus	69-95
8913345-7	1996	ACh enhanced the activity of cPLA2 and p42 mitogen-activated protein kinase (MAPK) in cell lysate prepared from CEC.	Acetylcholine	0-3	cytosolic phospholipase A2	Oryctolagus cuniculus	29-34
8913345-8	1996	ACh also caused phosphorylation of p42 MAPK and cPLA2, which was inhibited by AG126 ([alpha-cyano-(3-hydroxy-4-nitro)cinnamonitrile]), a tyrosine kinase inhibitor known to decrease MAPK activity.	Acetylcholine	0-3	cytosolic phospholipase A2	Oryctolagus cuniculus	48-53
8913345-8	1996	ACh also caused phosphorylation of p42 MAPK and cPLA2, which was inhibited by AG126 ([alpha-cyano-(3-hydroxy-4-nitro)cinnamonitrile]), a tyrosine kinase inhibitor known to decrease MAPK activity.	AG 127	78-83	cytosolic phospholipase A2	Oryctolagus cuniculus	48-53
8913345-8	1996	ACh also caused phosphorylation of p42 MAPK and cPLA2, which was inhibited by AG126 ([alpha-cyano-(3-hydroxy-4-nitro)cinnamonitrile]), a tyrosine kinase inhibitor known to decrease MAPK activity.	AG 127	86-131	cytosolic phospholipase A2	Oryctolagus cuniculus	48-53
8913345-9	1996	In addition, ACh stimulated translocation of cPLA2 from cytosol to nuclear envelope; the translocation of cPLA2 was prevented by removal of extracellular calcium but not by AG126 treatment.	Acetylcholine	13-16	cytosolic phospholipase A2	Oryctolagus cuniculus	45-50
8913345-9	1996	In addition, ACh stimulated translocation of cPLA2 from cytosol to nuclear envelope; the translocation of cPLA2 was prevented by removal of extracellular calcium but not by AG126 treatment.	Acetylcholine	13-16	cytosolic phospholipase A2	Oryctolagus cuniculus	106-111
8913345-9	1996	In addition, ACh stimulated translocation of cPLA2 from cytosol to nuclear envelope; the translocation of cPLA2 was prevented by removal of extracellular calcium but not by AG126 treatment.	Calcium	154-161	cytosolic phospholipase A2	Oryctolagus cuniculus	45-50
8913345-9	1996	In addition, ACh stimulated translocation of cPLA2 from cytosol to nuclear envelope; the translocation of cPLA2 was prevented by removal of extracellular calcium but not by AG126 treatment.	Calcium	154-161	cytosolic phospholipase A2	Oryctolagus cuniculus	106-111
8913345-10	1996	Okadaic acid, a protein phosphatase inhibitor, increased cPLA2 activity in cell lysate prepared from CEC but did not alter basal 6-keto-PGF1 alpha production in intact CEC; however, ACh-induced 6-keto-PGF1 alpha was enhanced by okadaic acid.	Okadaic Acid	0-12	cytosolic phospholipase A2	Oryctolagus cuniculus	57-62
8913345-10	1996	Okadaic acid, a protein phosphatase inhibitor, increased cPLA2 activity in cell lysate prepared from CEC but did not alter basal 6-keto-PGF1 alpha production in intact CEC; however, ACh-induced 6-keto-PGF1 alpha was enhanced by okadaic acid.	Acetylcholine	182-185	cytosolic phospholipase A2	Oryctolagus cuniculus	57-62
8913345-11	1996	These data suggest that ACh stimulates prostacyclin synthesis by activation of cPLA2 in a PKC-independent mechanism and that both cPLA2 translocation to nuclear envelope and phosphorylation by MAPK are required for ACh-induced 6-keto-PGF1 alpha synthesis in CEC.	Acetylcholine	24-27	cytosolic phospholipase A2	Oryctolagus cuniculus	79-84
8913345-11	1996	These data suggest that ACh stimulates prostacyclin synthesis by activation of cPLA2 in a PKC-independent mechanism and that both cPLA2 translocation to nuclear envelope and phosphorylation by MAPK are required for ACh-induced 6-keto-PGF1 alpha synthesis in CEC.	Epoprostenol	39-51	cytosolic phospholipase A2	Oryctolagus cuniculus	79-84
8913345-11	1996	These data suggest that ACh stimulates prostacyclin synthesis by activation of cPLA2 in a PKC-independent mechanism and that both cPLA2 translocation to nuclear envelope and phosphorylation by MAPK are required for ACh-induced 6-keto-PGF1 alpha synthesis in CEC.	Acetylcholine	215-218	cytosolic phospholipase A2	Oryctolagus cuniculus	130-135
8913345-11	1996	These data suggest that ACh stimulates prostacyclin synthesis by activation of cPLA2 in a PKC-independent mechanism and that both cPLA2 translocation to nuclear envelope and phosphorylation by MAPK are required for ACh-induced 6-keto-PGF1 alpha synthesis in CEC.	6-keto-pgf1	227-238	cytosolic phospholipase A2	Oryctolagus cuniculus	130-135
8719419-1	1995	The effect of berbamine, a biscoclaurine alkaloid, on cytosolic phospholipase A2 activation in rabbit platelets was investigated.	berbamine	14-23	cytosolic phospholipase A2	Oryctolagus cuniculus	54-80
8719419-8	1995	These results suggest that berbamine may impair GTP-binding protein-mediated activation of cytosolic phospholipase A2, probably without influencing the enzyme translocation to membranes or the increase in the enzyme activity, and thus may cause the suppression of thrombin-induced arachidonic acid liberation.	berbamine	27-36	cytosolic phospholipase A2	Oryctolagus cuniculus	91-117
8719419-8	1995	These results suggest that berbamine may impair GTP-binding protein-mediated activation of cytosolic phospholipase A2, probably without influencing the enzyme translocation to membranes or the increase in the enzyme activity, and thus may cause the suppression of thrombin-induced arachidonic acid liberation.	Guanosine Triphosphate	48-51	cytosolic phospholipase A2	Oryctolagus cuniculus	91-117
8180247-4	1994	In the present paper, we examined whether DHA-containing diacyl- and alkenylacylglycerophosphoethanolamine (DHA-diacylGPE and DHA-alkenylacyGPE) are susceptible to the action of AA-preferential 85 kDa cytosolic phospholipase A2 (cPLA2) from rabbit platelets in comparison with AA and eicosapentaenoic acid (EPA, 20:5(n - 3)) derivatives.	Docosahexaenoic Acids	42-45	cytosolic phospholipase A2	Oryctolagus cuniculus	229-234
7663381-5	1995	These results suggest that phosphorylation and translocation to membranes of cytosolic phospholipase A2 are necessary but not sufficient for arachidonic acid liberation by the enzyme upon receptor stimulation, and that another factor, such as GTP-binding protein, may be further required for the hydrolytic action of the enzyme.	Arachidonic Acid	141-157	cytosolic phospholipase A2	Oryctolagus cuniculus	77-103
7663381-5	1995	These results suggest that phosphorylation and translocation to membranes of cytosolic phospholipase A2 are necessary but not sufficient for arachidonic acid liberation by the enzyme upon receptor stimulation, and that another factor, such as GTP-binding protein, may be further required for the hydrolytic action of the enzyme.	Guanosine Triphosphate	243-246	cytosolic phospholipase A2	Oryctolagus cuniculus	77-103
8180247-4	1994	In the present paper, we examined whether DHA-containing diacyl- and alkenylacylglycerophosphoethanolamine (DHA-diacylGPE and DHA-alkenylacyGPE) are susceptible to the action of AA-preferential 85 kDa cytosolic phospholipase A2 (cPLA2) from rabbit platelets in comparison with AA and eicosapentaenoic acid (EPA, 20:5(n - 3)) derivatives.	Docosahexaenoic Acids	42-45	cytosolic phospholipase A2	Oryctolagus cuniculus	201-227
7803237-8	1994	In addition, a dissociation was observed between sPLA2 and the enzyme involved in the arachidonic acid mobilization, suggesting that the liberation of this fatty acid from membrane phospholipids was mediated by cytosolic phospholipase A2 (cPLA2).	Arachidonic Acid	86-102	cytosolic phospholipase A2	Oryctolagus cuniculus	211-237
7803237-8	1994	In addition, a dissociation was observed between sPLA2 and the enzyme involved in the arachidonic acid mobilization, suggesting that the liberation of this fatty acid from membrane phospholipids was mediated by cytosolic phospholipase A2 (cPLA2).	Fatty Acids	156-166	cytosolic phospholipase A2	Oryctolagus cuniculus	211-237
7803237-8	1994	In addition, a dissociation was observed between sPLA2 and the enzyme involved in the arachidonic acid mobilization, suggesting that the liberation of this fatty acid from membrane phospholipids was mediated by cytosolic phospholipase A2 (cPLA2).	Fatty Acids	156-166	cytosolic phospholipase A2	Oryctolagus cuniculus	239-244
7803237-8	1994	In addition, a dissociation was observed between sPLA2 and the enzyme involved in the arachidonic acid mobilization, suggesting that the liberation of this fatty acid from membrane phospholipids was mediated by cytosolic phospholipase A2 (cPLA2).	Phospholipids	181-194	cytosolic phospholipase A2	Oryctolagus cuniculus	211-237
7803237-8	1994	In addition, a dissociation was observed between sPLA2 and the enzyme involved in the arachidonic acid mobilization, suggesting that the liberation of this fatty acid from membrane phospholipids was mediated by cytosolic phospholipase A2 (cPLA2).	Phospholipids	181-194	cytosolic phospholipase A2	Oryctolagus cuniculus	239-244
8180247-4	1994	In the present paper, we examined whether DHA-containing diacyl- and alkenylacylglycerophosphoethanolamine (DHA-diacylGPE and DHA-alkenylacyGPE) are susceptible to the action of AA-preferential 85 kDa cytosolic phospholipase A2 (cPLA2) from rabbit platelets in comparison with AA and eicosapentaenoic acid (EPA, 20:5(n - 3)) derivatives.	alkenylacylglycerophosphoethanolamine	69-106	cytosolic phospholipase A2	Oryctolagus cuniculus	201-227